Q4 EPS Forecast for Bio-Rad Laboratories Boosted by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research boosted their Q4 2024 earnings per share estimates for Bio-Rad Laboratories in a research note issued on Thursday, February 6th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.87 per share for the quarter, up from their prior forecast of $2.86. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.33 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2025 earnings at $3.16 EPS.

BIO has been the topic of several other reports. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research report on Wednesday. Royal Bank of Canada reissued an "outperform" rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Citigroup upped their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and an average target price of $395.20.

Bio-Rad Laboratories Trading Down 2.5 %

Shares of Bio-Rad Laboratories stock traded down $7.79 on Monday, reaching $304.57. 375,656 shares of the company were exchanged, compared to its average volume of 169,823. The stock has a fifty day moving average price of $339.70 and a 200-day moving average price of $336.52. The firm has a market capitalization of $8.53 billion, a price-to-earnings ratio of -11.14 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories has a fifty-two week low of $262.12 and a fifty-two week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BIO. Metis Global Partners LLC boosted its stake in Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock valued at $234,000 after purchasing an additional 30 shares during the period. Signaturefd LLC boosted its stake in Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock valued at $87,000 after purchasing an additional 31 shares during the period. Avior Wealth Management LLC boosted its stake in Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company's stock valued at $334,000 after purchasing an additional 32 shares during the period. UMB Bank n.a. boosted its stake in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the period. Finally, Thrivent Financial for Lutherans boosted its stake in Bio-Rad Laboratories by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock valued at $1,488,000 after purchasing an additional 32 shares during the period. Hedge funds and other institutional investors own 65.24% of the company's stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.